{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:15Z","timestamp":1789593735394,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Secondary acute myeloid leukemia (AML) comprises heterogeneous entities, unified by poor prognosis. We evaluated the associations of genetic profiles with blast counts and patients\u2019 history in a cohort of 924 patients with myelodysplastic syndrome (MDS)\/AML or AML, classified according to the International Consensus Classification (ICC). The cohort included 109 patients with \u201cmutated TP53,\u201d 497 with \u201cmyelodysplasia-related (MDR) gene mutation,\u201d 93 with \u201cMDR-cytogenetic abnormality,\u201d 77 were therapy-related, and 136 controls, categorized as \u201cnot otherwise specified\u201d (NOS) AML. Exploring the ICC hierarchy, AML and MDS\/AML categories with \u201cmutated TP53\u201d and \u201cMDR-cytogenetic abnormality\u201d presented similar biology and prognosis, irrespective of blast counts. Conversely, in MDS\/AML with \u201cMDR gene mutation\u201d and NOS, profiles significantly differed from AML and were characterized by a higher number of mutations in STAG2, SRSF2, ASXL1 and TET2. This corresponded to improved survival in MDS\/AML vs AML (MDR-gene mutation: median overall survival 24.8 vs 13.6 months, P&amp;lt; .0001; and NOS: 49.9 vs 19.2 months, P = .028). Within each ICC-defined AML category, a prior MDS history vs de novo onset did not impact on patients\u2019 prognosis. We then analyzed secondary AML, defined by \u201cprior MDS or MDS\/MPN\u201d or \u201ctherapy-related\u201d (t-AML), as diagnostic qualifiers. According to European LeukemiaNet (ELN) 2022, AML progressing from MDS or MDS\/myeloproliferative neoplasm (MPN) (AML post-MDS) mostly clustered in the adverse-risk group (84.1%), whereas t-AML showed more heterogeneous ELN profiles (12.9% favorable, 33.8% intermediate, and 53.3% adverse risk) reflecting diverse overall survival. Our findings underscore that genetic features and the ICC classification reliably capture disease biology, refine risk stratification, and ultimately guide treatment decisions in most secondary AML and MDS\/AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018188","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:58:03Z","timestamp":1772737083000},"page":"3347-3356","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Validation of ICC hierarchical classification in secondary AML"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4801-5048","authenticated-orcid":false,"given":"Enrico","family":"Attardi","sequence":"first","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-8059","authenticated-orcid":false,"given":"Marta","family":"Cipriani","sequence":"additional","affiliation":[{"name":"2Department of Statistical Sciences, University of Rome La Sapienza, Rome, Italy"},{"name":"3Data Center and Health Outcomes Research Unit, GIMEMA Foundation, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-0663","authenticated-orcid":false,"given":"Luca","family":"Guarnera","sequence":"additional","affiliation":[{"name":"4Department of Biomedicine and Prevention, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy"},{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Savi","sequence":"additional","affiliation":[{"name":"6Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-8934","authenticated-orcid":false,"given":"Emiliano","family":"Fabiani","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Mallegni","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-5296","authenticated-orcid":false,"given":"Federico","family":"Moretti","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0665-6241","authenticated-orcid":false,"given":"Giorgia","family":"Silvestrini","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1445-7947","authenticated-orcid":false,"given":"Hussein","family":"Awada","sequence":"additional","affiliation":[{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-600X","authenticated-orcid":false,"given":"Arda","family":"Durmaz","sequence":"additional","affiliation":[{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9197-0701","authenticated-orcid":false,"given":"Ivan","family":"Ferrari","sequence":"additional","affiliation":[{"name":"7IRCCS Humanitas Clinical & Research Center and Department of Biomedical Sciences, Humanitas University, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-4854","authenticated-orcid":false,"given":"Giulia","family":"Maggioni","sequence":"additional","affiliation":[{"name":"7IRCCS Humanitas Clinical & Research Center and Department of Biomedical Sciences, Humanitas University, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Memoli","sequence":"additional","affiliation":[{"name":"8Department of Clinical Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Visconte","sequence":"additional","affiliation":[{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-5970","authenticated-orcid":false,"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[{"name":"7IRCCS Humanitas Clinical & Research Center and Department of Biomedical Sciences, Humanitas University, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"},{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-885X","authenticated-orcid":false,"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"4Department of Biomedicine and Prevention, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-4346","authenticated-orcid":false,"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"7","key":"2026052610372875100_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026052610372875100_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"17","key":"2026052610372875100_bib3","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026052610372875100_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: how to avoid a Babylonian confusion of languages","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"2026052610372875100_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2026052610372875100_bib6","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.2020010603","article-title":"Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia","volume":"138","author":"Awada","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026052610372875100_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026052610372875100_bib8","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"7728","key":"2026052610372875100_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"7","key":"2026052610372875100_bib10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2026052610372875100_bib11","author":"McGowan-Jordan","year":"2020"},{"issue":"4","key":"2026052610372875100_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2026052610372875100_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026052610372875100_bib14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"2026052610372875100_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026052610372875100_bib16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2026052610372875100_bib17","first-page":"263","article-title":"Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia","volume":"104","author":"Maffei","year":"2025","journal-title":"Ann Hematol"},{"issue":"9","key":"2026052610372875100_bib18","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2026052610372875100_bib19","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"17","key":"2026052610372875100_bib20","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1182\/bloodadvances.2023009675","article-title":"Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia","volume":"7","author":"McCarter","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026052610372875100_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2026052610372875100_bib22","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026052610372875100_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2026052610372875100_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"issue":"7954","key":"2026052610372875100_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2026052610372875100_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2026052610372875100_bib27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood.2022018108","article-title":"Overlapping features of therapy-related and de novo NPM1-mutated AML","volume":"141","author":"Othman","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2026052610372875100_bib28","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026052610372875100_bib29","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1002\/hem3.112","article-title":"Prospective genetic germline evaluation in a consecutive group of adult patients aged &lt;60 years with myelodysplastic syndromes","volume":"8","author":"Attardi","year":"2024","journal-title":"Hemasphere"},{"issue":"2","key":"2026052610372875100_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41568-020-00315-z","article-title":"Advances in germline predisposition to acute leukaemias and myeloid neoplasms","volume":"21","author":"Klco","year":"2021","journal-title":"Nat Rev Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3347\/2518736\/blooda_adv-2025-018188-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3347\/2518736\/blooda_adv-2025-018188-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:41Z","timestamp":1779806261000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3347\/566934\/Validation-of-ICC-hierarchical-classification-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018188","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,13]]}}}